The relative risk of developing BC has been described for truncating variants in BRCA2 (relative risk: 11.7), while ATM and CHEK2 truncating variants have relative risks of 2.8 (2.2–3.7) and 3.0 (2.6–3.5), respectively48. Here, CHEK2 is linked to breast cancer.